Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance
作者： Eva Martinez-Balibrea , Anna Martínez-Cardús , Alba Ginés , Vicenç Ruiz de Porras , Catia Moutinho
DOI: 10.1158/1535-7163.MCT-14-0636
关键词:
摘要: Oxaliplatin was the first platinum drug with proven activity against colorectal tumors, becoming a standard in management of this malignancy. It is also considered for treatment pancreatic and gastric cancers. However, major reason failure still existence tumor intrinsic or acquired resistance. Consequently, it important to understand molecular mechanisms underlying appearance phenomenon find ways circumventing improve optimize treatments. This review will be focused on recent discoveries about oxaliplatin tumor-related resistance mechanisms, including alterations transport, detoxification, DNA damage response repair, cell death (apoptotic nonapoptotic), epigenetic mechanisms.
aacrjournals.org
sci-hub.se 参考文章(104)
Eva Martinez-Balibrea, Anna Martínez-Cardús, Eva Musulén, Alba Ginés, José Luis Manzano, Enrique Aranda, Carmen Plasencia, Nouri Neamati, Albert Abad, Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy International Journal of Cancer. ,vol. 124, pp. 2905- 2910 ,(2009) , 10.1002/IJC.24273
Barbara Köhler, Sergio Anguissola, Caoimhin G Concannon, Markus Rehm, Donat Kögel, Jochen HM Prehn, None, Bid Participates in Genotoxic Drug-Induced Apoptosis of HeLa Cells and Is Essential for Death Receptor Ligands' Apoptotic and Synergistic Effects PLoS ONE. ,vol. 3, pp. e2844- ,(2008) , 10.1371/JOURNAL.PONE.0002844
Saeed Ahmad, Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chemistry & Biodiversity. ,vol. 7, pp. 543- 566 ,(2010) , 10.1002/CBDV.200800340
D Tang, R Kang, C-W Cheh, K M Livesey, X Liang, N E Schapiro, R Benschop, L J Sparvero, A A Amoscato, K J Tracey, H J Zeh, M T Lotze, HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene. ,vol. 29, pp. 5299- 5310 ,(2010) , 10.1038/ONC.2010.261
J.B. Kjersem, T. Ikdahl, O.C. Lingjaerde, T. Guren, K.M. Tveit, E.H. Kure, Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Molecular Oncology. ,vol. 8, pp. 59- 67 ,(2014) , 10.1016/J.MOLONC.2013.09.001
R Perona, I Sánchez-Pérez, Control of oncogenesis and cancer therapy resistance. British Journal of Cancer. ,vol. 90, pp. 573- 577 ,(2004) , 10.1038/SJ.BJC.6601552
Peter Mu-Hsin Chang, Cheng-Hwai Tzeng, Po-Min Chen, Jen-Kou Lin, Tzu-Chen Lin, Wei-Shone Chen, Jeng-Kae Jiang, Huann-Sheng Wang, Wei-Shu Wang, ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX‐4 treatment in Asian patients with metastatic colorectal carcinoma Cancer Science. ,vol. 100, pp. 278- 283 ,(2009) , 10.1111/J.1349-7006.2008.01031.X
Florent Toscano, Béatrice Parmentier, Zineb El Fajoui, Yann Estornes, Jean-Alain Chayvialle, Jean-Christophe Saurin, Jacques Abello, p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells Biochemical Pharmacology. ,vol. 74, pp. 392- 406 ,(2007) , 10.1016/J.BCP.2007.05.001
Ahmad R. Safa, Karen E. Pollok, Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy Cancers. ,vol. 3, pp. 1639- 1671 ,(2011) , 10.3390/CANCERS3021639
Wan Zhang, Dunyaporn Trachootham, Jinyun Liu, Gang Chen, Helene Pelicano, Celia Garcia-Prieto, Weiqin Lu, Jan A. Burger, Carlo M. Croce, William Plunkett, Michael J. Keating, Peng Huang, Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nature Cell Biology. ,vol. 14, pp. 276- 286 ,(2012) , 10.1038/NCB2432